Results 51 to 60 of about 9,412 (255)

Isolated fever induced by mesalamine treatment

World Journal of Gastroenterology, 2013
Adverse reactions to mesalamine, a treatment used to induce and maintain remission in inflammatory bowel diseases, particularly ulcerative colitis, have been described in the literature as case reports. This case illustrates an unusual adverse reaction.
Roy Nasnas, Raymond Sayegh, Joseph Amara, Joseph Bou Jaoude, Cesar Yaghi, Rita Slim, Khalil Honein, Fady Daniel   +7 more
openaire   +2 more sources

Have we hit the JAK‐pot? Success of selective JAK 1 inhibitor following failure of pan‐JAK inhibitor in refractory pediatric ulcerative colitis

JPGN Reports, EarlyView.
Abstract The treatment options available for pediatric ulcerative colitis (UC) are challenging due to few with Federal Drug Administration approval. Newer medications approved for adults include additional biologics with differing mechanisms of action and small molecule drugs, such as Janus kinase (JAK) inhibitors.
Jessica A. Black, Brad Pasternak
wiley   +1 more source

One of the 5-aminosalicylates drug, mesalamine as a drug repurposing lead against breast cancer

Bulletin of the National Research Centre, 2022
Background Breast cancer is the world's second leading cause of death in women. The problem of chemoresistance in breast cancer is proving to be a challenge for researchers and several oncologists all around the world.
Dayanand Swami, Shafina Siddiqui, Urwashi Kumar, Shine Devarajan, Jyotirmoi Aich   +4 more
doaj   +1 more source

A case report of successful band ligation of bleeding anastomotic duodenal varix in an adolescent patient

JPGN Reports, EarlyView.
Abstract Ectopic varices are defined as portosystemic venous collaterals occurring in the gastrointestinal tract outside of the cardio‐esophageal region. Duodenal varices are not routinely encountered by pediatric gastroenterologists. At the time of this case report, there are no consensus guidelines on the management of bleeding duodenal varices in ...
Lauren E. Hamilton, Joshua Carroll, Paul Tran   +2 more
wiley   +1 more source

Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers

Clinical Pharmacology: Advances and Applications, 2019
Abhijeet Jakate,1 Brian McNamee,2 Donald Burkindine31Clinical Pharmacology, Allergan plc, Madison, NJ, USA; 2Clinical Pharmacology, Allergan Biologics Ltd, Liverpool, UK; 3QPS Bio-Kinetic, Springfield, MO, USAObjective: Delayed-release mesalamine 400 mg ...
Jakate A, McNamee B, Burkindine D
doaj  

Induction of Colonic Regulatory T Cells by Mesalamine by Activating the Aryl Hydrocarbon ReceptorSummary

Cellular and Molecular Gastroenterology and Hepatology, 2017
Background & Aims: Mesalamine is a first-line drug for treatment of inflammatory bowel diseases (IBD). However, its mechanisms are not fully understood. CD4+ Foxp3+ regulatory T cells (Tregs) play a potential role in suppressing IBD.
Kyoko Oh-oka, Yuko Kojima, Koichiro Uchida, Kimiko Yoda, Kayoko Ishimaru, Shotaro Nakajima, Jun Hemmi, Hiroshi Kano, Yoshiaki Fujii-Kuriyama, Ryohei Katoh, Hiroyuki Ito, Atsuhito Nakao   +11 more
doaj  

Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background Leishmaniasis (LI) is a vector‐borne illness caused by a protozoan of the genus Leishmania. Data on the features of LI in patients with inflammatory bowel disease (IBD) are scarce. Aim To describe the characteristics of patients with IBD who present with leishmaniasis, infection outcomes and the risk factors associated with ...
L Madero‐Velázquez, A Mínguez, L Mayorga, JJ Ramírez, N Moreno, C Amorós, MA Nieto, R Mena, JM Benítez, L Gimeno‐Pitarch, N Maroto, C Suria, F Rodríguez‐Moranta, I Ordás, L Ruiz, MA García‐Brenes, A Martín‐Cardona, C Rubín de Célix, K Cárdenas, D Ginard, L Medina, N Pedrero, R Plaza, R Salmoral, TJ Martínez‐Pérez, V Algara, E Merino, Y Zabana, A Gutiérrez, on behalf of Young Group of GETECCU   +29 more
wiley   +1 more source

Design, Development, and Optimisation of Smart Linker Chemistry for Targeted Colonic Delivery—In Vitro Evaluation

Pharmaceutics, 2023
Drug targeting is necessary to deliver drugs to a specific site of action at a rate dictated by therapeutic requirements. The pharmacological action of a drug can thereby be optimised while minimising adverse effects.
Heba S. Abd-Ellah, Ramesh Mudududdla, Glen P. Carter, Jonathan B. Baell   +3 more
doaj   +1 more source

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine

Clinical Pharmacology: Advances and Applications, 2012
Kavinderjit Nanda, Alan C MossCenter for Inflammatory Bowel Disease, BIDMC/Harvard Medical School, Boston, MA, USAAbstract: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and ...
Nanda K, Moss AC
doaj  

Water-in-Water Emulsion as a New Approach to Produce Mesalamine-Loaded Xylan-Based Microparticles

Applied Sciences, 2019
The water-in-water emulsion method has been reported as a technique able to prepare microparticles without using harmful solvents. However, there are few reports showing the encapsulation of small molecules into microparticles produced within this ...
Bartolomeu S. Souza, Henrique R. Marcelino, Francisco Alexandrino, Silvana C. C. Urtiga, Karen C. H. Silva, Daniel C. F. Soares, Eryvaldo S. T. Egito   +6 more
doaj   +1 more source